Noboru Hara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noboru Hara has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Kota Takahashi
Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
30 shared publicationsTsutomu Nishiyama
Niigata City, Japan
20 shared publicationsVladimir Bilim
Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan
11 shared publicationsItsuhiro Takizawa
Division of Urology Department of Regenerative and Transplant Medicine Graduate School of Medical and Dental Sciences Niigata University Niigata Japan
10 shared publicationsToshihiro Saito
Department of Urology
8 shared publications- Yoshihiko Tomita
Department of Urology, Yamagata University School of Medicine, Yamagata, Japan
8 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (5) , 508-512
A Case of Complete Remission Achieved Through Stereotactic Radiotherapy for Isolated Bone Metastasis Following Four Courses of Bleomycin, Etoposide, and Cisplatin Chemotherapy for Testicular Cancer
Introduction: We report a case of nonseminoma germ cell tumor, in which solitary bone metastasis was detected by magnetic resonance imaging (MRI) after systemic chemotherapy, and resolution was achieved with stereotactic radiotherapy.Case Presentation: A 42‐year‐old man was diagnosed with right‐sided testicular cancer, T1N1M0, and right high orchiectomy was performed. Pathology revealed a mixed germ cell tumor. He received four 3‐week courses of chemotherapy (BEP). Although computed tomography showed no new metastases, whole‐body MRI revealed a solitary bone metastasis to the left sacrum, and stereotactic radiotherapy of 36.8 Gy/8f was administered to the same area. After radiotherapy, the accumulation in that area disappeared on MRI.Conclusion: As evidence accumulates, it is likely that whole‐body MRI will become a useful observational method for staging and monitoring patients with germ cell tumors. Stereotactic radiotherapy may be used as consolidation therapy for patients with residual masses after systemic therapy.
- 13 August 2025
- Published by Wiley in IJU Case Reports
- Vol. 8 (5) , 508-512
Open AccessA Case of Complete Remission Achieved Through Stereotactic Radiotherapy for Isolated Bone Metastasis Following Four Courses of Bleomycin, Etoposide, and Cisplatin Chemotherapy for Testicular Cancer
Introduction: We report a case of nonseminoma germ cell tumor, in which solitary bone metastasis was detected by magnetic resonance imaging (MRI) after systemic chemotherapy, and resolution was achieved with stereotactic radiotherapy.Case Presentation: A 42‐year‐old man was diagnosed with right‐sided testicular cancer, T1N1M0, and right high orchiectomy was performed. Pathology revealed a mixed germ cell tumor. He received four 3‐week courses of chemotherapy (BEP). Although computed tomography showed no new metastases, whole‐body MRI revealed a solitary bone metastasis to the left sacrum, and stereotactic radiotherapy of 36.8 Gy/8f was administered to the same area. After radiotherapy, the accumulation in that area disappeared on MRI.Conclusion: As evidence accumulates, it is likely that whole‐body MRI will become a useful observational method for staging and monitoring patients with germ cell tumors. Stereotactic radiotherapy may be used as consolidation therapy for patients with residual masses after systemic therapy.
- Open Access
- 11 November 2022
- Published by Wiley in IJU Case Reports
- Vol. 6 (1) , 85-88
Primary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer
Introduction: We report a patient with the complete remission of multiple metastases and primary bladder lesions of bladder cancer who developed primary lung cancer requiring radical resection.Case presentation: A 68‐year‐old man diagnosed with invasive bladder cancer, right hydroureteronephrosis, and multiple metastases were administered six courses of gemcitabine and carboplatin chemotherapy and thereafter has been receiving pembrolizumab therapy. Bladder cancer and multiple metastases decreased in size, whereas a ground‐glass opacity lesion in the lung gradually increased in size. Fluorodeoxyglucose‐positron emission tomography revealed the accumulation of fluorodeoxyglucose in the ground‐glass opacity lesion only. The patient was diagnosed with primary lung cancer and underwent a thoracoscopic lobectomy. Histopathological findings showed ALK‐negative, EGFR L858R mutation‐positive invasive adenocarcinoma with a programmed death‐ligand 1 tumor proportion score of less than 1%.Conclusion: This is the first case report of patients with the complete remission of multiple metastases of bladder cancer who developed primary lung cancer requiring radical resection.
- 11 November 2022
- Published by Wiley in IJU Case Reports
- Vol. 6 (1) , 85-88
Open AccessPrimary lung cancer treatable with radical resection after complete remission with pembrolizumab therapy following gemcitabine and carboplatin chemotherapy for multiple metastases of bladder cancer
Introduction: We report a patient with the complete remission of multiple metastases and primary bladder lesions of bladder cancer who developed primary lung cancer requiring radical resection.Case presentation: A 68‐year‐old man diagnosed with invasive bladder cancer, right hydroureteronephrosis, and multiple metastases were administered six courses of gemcitabine and carboplatin chemotherapy and thereafter has been receiving pembrolizumab therapy. Bladder cancer and multiple metastases decreased in size, whereas a ground‐glass opacity lesion in the lung gradually increased in size. Fluorodeoxyglucose‐positron emission tomography revealed the accumulation of fluorodeoxyglucose in the ground‐glass opacity lesion only. The patient was diagnosed with primary lung cancer and underwent a thoracoscopic lobectomy. Histopathological findings showed ALK‐negative, EGFR L858R mutation‐positive invasive adenocarcinoma with a programmed death‐ligand 1 tumor proportion score of less than 1%.Conclusion: This is the first case report of patients with the complete remission of multiple metastases of bladder cancer who developed primary lung cancer requiring radical resection.
- Open Access
- 28 May 2021
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2021, 1-4
Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
A 70-year-old woman was referred to our hospital with gross hematuria and diagnosed with right invasive ureteral cancer and bladder urothelial carcinoma in situ. Intravesical BCG therapy and neoadjuvant chemotherapy with carboplatin and gemcitabine were performed at the same time. Subsequently, laparoscopic right nephroureterectomy was performed. Urothelial carcinoma in situ persisted; however, most of the tumor was clear cell carcinoma. The clear cell carcinoma lesion had clear cytoplasm with round nuclei and visible nucleoli in an insular arrangement as is the case with clear cell renal cell carcinoma. No transitional lesion between clear cell adenocarcinoma and urothelial carcinoma was presented. The clear cell carcinoma lesion was GATA3 negative and HNF4α positive; however, the urothelial cancer lesion was GATA3 positive and HNF4α negative. Clear cell carcinoma was diagnosed as clear cell adenocarcinoma similar to clear cell renal cell carcinoma histology.
- 28 May 2021
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2021, 1-4
Open AccessClear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
A 70-year-old woman was referred to our hospital with gross hematuria and diagnosed with right invasive ureteral cancer and bladder urothelial carcinoma in situ. Intravesical BCG therapy and neoadjuvant chemotherapy with carboplatin and gemcitabine were performed at the same time. Subsequently, laparoscopic right nephroureterectomy was performed. Urothelial carcinoma in situ persisted; however, most of the tumor was clear cell carcinoma. The clear cell carcinoma lesion had clear cytoplasm with round nuclei and visible nucleoli in an insular arrangement as is the case with clear cell renal cell carcinoma. No transitional lesion between clear cell adenocarcinoma and urothelial carcinoma was presented. The clear cell carcinoma lesion was GATA3 negative and HNF4α positive; however, the urothelial cancer lesion was GATA3 positive and HNF4α negative. Clear cell carcinoma was diagnosed as clear cell adenocarcinoma similar to clear cell renal cell carcinoma histology.
- Open Access
- 17 October 2019
- Published by Hindawi Limited in Prostate Cancer
- Vol. 2019, 1-6
Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer
Background. To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer. Methods. In total, 204 patients with the National Comprehensive Cancer Network (NCCN) high risk locally advanced prostate cancer (PSA > 20 ng/ml, Gleason score ≧ 8, clinical T stage ≧ 3a) were treated with definitive RT with ADT. Median follow up period was 113 months (IQR: 95–128). Median neoadjuvant ADT and total ADT duration were 7 months (IQR: 6–10) and 27 months (IQR: 14–38), respectively. Results. PSA recurrence-free survival (PSA-RFS), cancer specific survival (CSS), and overall survival (OS) rates at 5 years were 84.1%, 98.5%, and 93.6%, respectively, and 67.9%, 91.2%, and 78.1%, respectively, at 10 years. Pre-RT PSA less than 0.2 ng/ml was associated with superior outcomes of PSA-RFS (HR = 0.42, 95% CI: 0.25–0.70, ), CSS (HR = 0.27, 95% CI: 0.09–0.82, ), and OS (HR = 0.48, 95% CI: 0.26–0.91, ). On multivariate analysis, age (≥70 y.o.) and pre-RT PSA (≥0.2 ng/ml) were factors predictive of poorer OS () , but iPSA, T stage, Gleason score, number of NCCN high-risk criteria, a combination with anti-androgen therapy and neoadjuvant ADT duration were not predictive of treatment outcome. Conclusion. In patient with high-risk prostate cancer, RT plus ADT achieved good oncologic outcomes. PSA < 0.2 ng/ml before radiation therapy is a strong independent predictor for long overall survival.
- 17 October 2019
- Published by Hindawi Limited in Prostate Cancer
- Vol. 2019, 1-6
Open AccessAchieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer
Background. To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer. Methods. In total, 204 patients with the National Comprehensive Cancer Network (NCCN) high risk locally advanced prostate cancer (PSA > 20 ng/ml, Gleason score ≧ 8, clinical T stage ≧ 3a) were treated with definitive RT with ADT. Median follow up period was 113 months (IQR: 95–128). Median neoadjuvant ADT and total ADT duration were 7 months (IQR: 6–10) and 27 months (IQR: 14–38), respectively. Results. PSA recurrence-free survival (PSA-RFS), cancer specific survival (CSS), and overall survival (OS) rates at 5 years were 84.1%, 98.5%, and 93.6%, respectively, and 67.9%, 91.2%, and 78.1%, respectively, at 10 years. Pre-RT PSA less than 0.2 ng/ml was associated with superior outcomes of PSA-RFS (HR = 0.42, 95% CI: 0.25–0.70, ), CSS (HR = 0.27, 95% CI: 0.09–0.82, ), and OS (HR = 0.48, 95% CI: 0.26–0.91, ). On multivariate analysis, age (≥70 y.o.) and pre-RT PSA (≥0.2 ng/ml) were factors predictive of poorer OS () , but iPSA, T stage, Gleason score, number of NCCN high-risk criteria, a combination with anti-androgen therapy and neoadjuvant ADT duration were not predictive of treatment outcome. Conclusion. In patient with high-risk prostate cancer, RT plus ADT achieved good oncologic outcomes. PSA < 0.2 ng/ml before radiation therapy is a strong independent predictor for long overall survival.
- Open Access
- 28 August 2019
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2019, 1-4
Simultaneous Laparoscopic Surgery for Bladder Diverticulum and Urachal Remnant: A Case Report
A 44-year-old woman visited a hospital with microscopic hematuria in June 2009. Computed tomography showed a large bladder diverticulum at right lateral wall and urachal remnant. Cystoscopic examination showed a large diverticulum at the right lateral wall that closes to the dome. She was followed up closely without therapeutic intervention; however, the residual urine increased gradually and frequent bladder diverticulitis developed. She underwent laparoscopic bladder diverticulectomy and excision of the urachal remnant simultaneously without any complications in August 2017. Laparoscopic approach for a large bladder diverticulum and urachal remnant is useful with safe, effective, and minimally invasive.
- 28 August 2019
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2019, 1-4
Open AccessSimultaneous Laparoscopic Surgery for Bladder Diverticulum and Urachal Remnant: A Case Report
A 44-year-old woman visited a hospital with microscopic hematuria in June 2009. Computed tomography showed a large bladder diverticulum at right lateral wall and urachal remnant. Cystoscopic examination showed a large diverticulum at the right lateral wall that closes to the dome. She was followed up closely without therapeutic intervention; however, the residual urine increased gradually and frequent bladder diverticulitis developed. She underwent laparoscopic bladder diverticulectomy and excision of the urachal remnant simultaneously without any complications in August 2017. Laparoscopic approach for a large bladder diverticulum and urachal remnant is useful with safe, effective, and minimally invasive.
- Open Access
- 31 October 2018
- Published by Wiley in IJU Case Reports
- Vol. 2 (1) , 9-11
Enzalutamide‐induced severe thrombocytopenia complicated by a seizure in a 76‐year‐old man with castration‐resistant prostate cancer
Introduction: Adverse events with enzalutamide widely used for men with castration‐resistant prostate cancer are of interest.Case presentation: A 76‐year‐old man developed castration‐resistant prostate cancer. He received 160 mg of enzalutamide daily. On the 13th day after treatment, severe thrombocytopenia was observed (platelet count: 1.9 × 104/μL). Normal coagulation and fibrinolytic systems suggested thrombocytopenia induced by enzalutamide. Enzalutamide was withdrawn immediately, and platelet count uneventfully recovered to 7.0 × 104/μL and 28.8 × 104/μL 9 and 30 days after discontinuation, respectively. He restarted enzalutamide therapy without thrombocytopenia recurrence. However, 81 days after restarting enzalutamide, he experienced a seizure. There were no significant findings from brain computed tomography, which suggested that the seizure was also an enzalutamide‐associated adverse event.Conclusion: Thrombocytopenia may occur early following enzalutamide therapy, and blood analysis within 2 weeks after treatment may facilitate its management. Enzalutamide‐induced thrombocytopenia, complicated by seizure, has not been reported.
- 31 October 2018
- Published by Wiley in IJU Case Reports
- Vol. 2 (1) , 9-11
Open AccessEnzalutamide‐induced severe thrombocytopenia complicated by a seizure in a 76‐year‐old man with castration‐resistant prostate cancer
Introduction: Adverse events with enzalutamide widely used for men with castration‐resistant prostate cancer are of interest.Case presentation: A 76‐year‐old man developed castration‐resistant prostate cancer. He received 160 mg of enzalutamide daily. On the 13th day after treatment, severe thrombocytopenia was observed (platelet count: 1.9 × 104/μL). Normal coagulation and fibrinolytic systems suggested thrombocytopenia induced by enzalutamide. Enzalutamide was withdrawn immediately, and platelet count uneventfully recovered to 7.0 × 104/μL and 28.8 × 104/μL 9 and 30 days after discontinuation, respectively. He restarted enzalutamide therapy without thrombocytopenia recurrence. However, 81 days after restarting enzalutamide, he experienced a seizure. There were no significant findings from brain computed tomography, which suggested that the seizure was also an enzalutamide‐associated adverse event.Conclusion: Thrombocytopenia may occur early following enzalutamide therapy, and blood analysis within 2 weeks after treatment may facilitate its management. Enzalutamide‐induced thrombocytopenia, complicated by seizure, has not been reported.
- Open Access
- 20 October 2017
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 108 (4) , 210-214
LEIOMYOSARCOMA OF THE OVARIAN VEIN WITH THE RENAL VEIN INVASION: A CASE REPORT
症例は56歳女性.左側腹部痛を主訴に他院を受診し,腹部CTにて左腎門部尾側に5cm大の後腹膜腫瘍を認め当院紹介となった.内分泌学的検査は正常で腫瘍マーカーの上昇なく,画像上の質的診断も困難なため後腹膜腫瘍摘出術を施行した.術中所見では,後腹膜腫瘍は左腎静脈と左卵巣静脈と連続しており,左腎静脈の中枢側まで浸潤していたため左腎を合併切除した.病理所見では,左卵巣静脈の平滑筋層から発生し左腎静脈に浸潤する平滑筋肉腫であった.術後21カ月で再発なく経過観察中である.本症例は卵巣静脈発生の平滑筋肉腫の18例目であり,腎静脈浸潤を伴う卵巣静脈原発平滑筋肉腫の3例目であった.
- 20 October 2017
- Published by Japanese Urological Association in The Japanese Journal of Urology
- Vol. 108 (4) , 210-214
Open AccessLEIOMYOSARCOMA OF THE OVARIAN VEIN WITH THE RENAL VEIN INVASION: A CASE REPORT
症例は56歳女性.左側腹部痛を主訴に他院を受診し,腹部CTにて左腎門部尾側に5cm大の後腹膜腫瘍を認め当院紹介となった.内分泌学的検査は正常で腫瘍マーカーの上昇なく,画像上の質的診断も困難なため後腹膜腫瘍摘出術を施行した.術中所見では,後腹膜腫瘍は左腎静脈と左卵巣静脈と連続しており,左腎静脈の中枢側まで浸潤していたため左腎を合併切除した.病理所見では,左卵巣静脈の平滑筋層から発生し左腎静脈に浸潤する平滑筋肉腫であった.術後21カ月で再発なく経過観察中である.本症例は卵巣静脈発生の平滑筋肉腫の18例目であり,腎静脈浸潤を伴う卵巣静脈原発平滑筋肉腫の3例目であった.
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e1113
MP83-18 A 21-CARBON STEROIDAL METABOLITE FROM PROGESTIN, 20β-DIHYDRO-5α-DIHYDROPROGESTERONE, STIMULATES THE ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS
Under androgen deprivation therapy (ADT), 21-carbon steroids (C21s), such as progesterone (P4) and glucocorticoids, accumulate in men with prostate cancer (PCa). Accumulated C21s could stimulate the progesterone receptor (PGR) or glucocorticoid receptor (GR) on PCa cells, and a relationship between these stimulations and castration resistance in PCa has been suggested. However, although the intra-tumoral metabolism of C21s in PCa cells exists, it is not known whether intracrine C21s are implicated in PCa progression. In this study, we showed that 20β-dihydro-5α-dihydroprogesterone (20β-OHDHP), a C21 and a metabolite of P4, was synthesized in PCa cells and was able to directly stimulate the androgen receptor.
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4) , e1113
MP83-18 A 21-CARBON STEROIDAL METABOLITE FROM PROGESTIN, 20β-DIHYDRO-5α-DIHYDROPROGESTERONE, STIMULATES THE ANDROGEN RECEPTOR IN PROSTATE CANCER CELLS
Under androgen deprivation therapy (ADT), 21-carbon steroids (C21s), such as progesterone (P4) and glucocorticoids, accumulate in men with prostate cancer (PCa). Accumulated C21s could stimulate the progesterone receptor (PGR) or glucocorticoid receptor (GR) on PCa cells, and a relationship between these stimulations and castration resistance in PCa has been suggested. However, although the intra-tumoral metabolism of C21s in PCa cells exists, it is not known whether intracrine C21s are implicated in PCa progression. In this study, we showed that 20β-dihydro-5α-dihydroprogesterone (20β-OHDHP), a C21 and a metabolite of P4, was synthesized in PCa cells and was able to directly stimulate the androgen receptor.
- Open Access
- 25 May 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen
Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostate cancer cells treated with AR ligands. We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs, respectively, to clarify the significance of NCOAs in the effect of antiandrogens. Hydroxyflutamide showed antagonistic activity against VCaP and an agonistic effect on LNCaP. Bicalutamide served as an antagonist for both. We analyzed mRNA transcription and protein expression of NCOAs in these cells pretreated with dihydrotestosterone and thereafter treated with the mentioned antiandrogens. Transcriptional silencing of candidate NCOAs and AR was performed using small interfering RNA (siRNA). Cell proliferation was evaluated with MTT assay. LNCaP treated with bicalutamide showed an about four-fold increase in the expression of NCOA2 mRNA compared to those pretreated with dihydrotestosterone alone (P <0.01). In VCaP pretreated with dihydrotestosterone, transcriptions of NCOA2 and NCOA7 were slightly increased with bicalutamide (1.96- and 2.42-fold, respectively) and hydroxyflutamide (1.33-fold in both). With Western blotting, the expression of NCOA2 protein also increased in LNCaP cells treated with bicalutamide compared with that in control cells pretreated with dihydrotestosterone alone. Following silencing with siRNA for NCOA2, PSA levels in media with LNCaP receiving bicalutamide were elevated compared with those in non-silencing controls (101.6 ± 4.2 vs. 87.8 ± 1.4 ng/mL, respectively, P =0.0495). In LNCaP cells treated with dihydrotestosterone and bicalutamide, NCOA2-silencing was associated with a higher proliferation activity compared with non-silencing control and AR-silencing. NCOA2, which has been thought to be recruited as a coactivator, possibly plays a corepressive role in AR of prostate cancer cells when treated with antiandrogens, suggesting its potential as a therapeutic target.
- 25 May 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Open AccessCorepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen
Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostate cancer cells treated with AR ligands. We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs, respectively, to clarify the significance of NCOAs in the effect of antiandrogens. Hydroxyflutamide showed antagonistic activity against VCaP and an agonistic effect on LNCaP. Bicalutamide served as an antagonist for both. We analyzed mRNA transcription and protein expression of NCOAs in these cells pretreated with dihydrotestosterone and thereafter treated with the mentioned antiandrogens. Transcriptional silencing of candidate NCOAs and AR was performed using small interfering RNA (siRNA). Cell proliferation was evaluated with MTT assay. LNCaP treated with bicalutamide showed an about four-fold increase in the expression of NCOA2 mRNA compared to those pretreated with dihydrotestosterone alone (P <0.01). In VCaP pretreated with dihydrotestosterone, transcriptions of NCOA2 and NCOA7 were slightly increased with bicalutamide (1.96- and 2.42-fold, respectively) and hydroxyflutamide (1.33-fold in both). With Western blotting, the expression of NCOA2 protein also increased in LNCaP cells treated with bicalutamide compared with that in control cells pretreated with dihydrotestosterone alone. Following silencing with siRNA for NCOA2, PSA levels in media with LNCaP receiving bicalutamide were elevated compared with those in non-silencing controls (101.6 ± 4.2 vs. 87.8 ± 1.4 ng/mL, respectively, P =0.0495). In LNCaP cells treated with dihydrotestosterone and bicalutamide, NCOA2-silencing was associated with a higher proliferation activity compared with non-silencing control and AR-silencing. NCOA2, which has been thought to be recruited as a coactivator, possibly plays a corepressive role in AR of prostate cancer cells when treated with antiandrogens, suggesting its potential as a therapeutic target.
- Open Access
- 2 November 2015
- Published by Wiley in International Journal of Urology
- Vol. 23 (2) , 132-7
Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery.
- 2 November 2015
- Published by Wiley in International Journal of Urology
- Vol. 23 (2) , 132-7
Open AccessClinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery.